MAbSilicoMAbSilico provides a formal embedded Artificial Intelligence technology for antibody discovery, reducing the risks of failure and the duration of discovery and preclinical steps, as well as strengthening intellectual property protection. Conventional approaches for the drug discovery take up to three years, while MAbSilico technologies allow shrinking this time to a few weeks. With lead selection, characterization and optimization, MAbSilico gives you AI-based solutions using antibody sequences and delivering qualified data within 10 days.
